Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RISE: Immunomodulatory Interventions in Long COVID
NCT06597682Not yet recruiting
- Sponsor
- Huashan Hospital
- Start
- Mar 2025
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of prednisone, EPI-EE and formoterol in post-acute sequelae of SARS-CoV-2 infection (PASC) (6 arms), sponsored by Huashan Hospital. Primary endpoints: Cardiac Magnetic Resonance indicators at 4 weeks, Leicester Cough Questionnaire scale scores at 8 weeks and 1 more. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
prednisoneEPI-EEformoterol
03
Conditions
post-acute sequelae of SARS-CoV-2 infection (PASC)
Beyond the preview
Go deeper on NCT06597682.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06597682.